HighTower Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

HighTower Advisors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$241K	Sell	3,430 -194	-5%	-$13.6K	﹤0.01%	3348
2025 Q4	$297K	Sell	3,624 -65	-2%	-$4.85K	﹤0.01%	3056
2025 Q3	$219K	Buy	+3,689	New	+$182K	﹤0.01%	3296
2025 Q1	–	Sell	-3,734	Closed	-$207K	–	4043
2024 Q4	$207K	Buy	+3,734	New	+$170K	﹤0.01%	3175

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HighTower Advisors's TARS Position: Q1 2026 in Review

HighTower Advisors reduced its Tarsus Pharmaceuticals (TARS) stake by 5.4% in Q1 2026, selling an estimated $13.6K and leaving 3,430 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

HighTower Advisors first reported a position in TARS in Q4 2024 and has held it in 4 quarters since. The position peaked at $297K in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

HighTower Advisors held 3,430 shares of Tarsus Pharmaceuticals worth $241K as of Q1 2026.
HighTower Advisors sold 194 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $13.6K.
Tarsus Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3348 holding.
HighTower Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
HighTower Advisors's Tarsus Pharmaceuticals position peaked at $297K in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.